Last reviewed · How we verify
shark cartilage extract AE-941
AE-941, a shark cartilage extract, is thought to inhibit angiogenesis.
AE-941, a shark cartilage extract, is thought to inhibit angiogenesis. Used for Metastatic colorectal cancer.
At a glance
| Generic name | shark cartilage extract AE-941 |
|---|---|
| Also known as | AE-941, Neovastat, Neovastat/AE-941 |
| Sponsor | AEterna Zentaris |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action is unclear, but AE-941 may interfere with the formation of new blood vessels, which can be beneficial in treating certain types of cancer. This is based on the presence of anti-angiogenic compounds in shark cartilage.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- AE-941 in Treating Patients With Metastatic Kidney Cancer (PHASE3)
- AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma (PHASE2)
- Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- shark cartilage extract AE-941 CI brief — competitive landscape report
- shark cartilage extract AE-941 updates RSS · CI watch RSS
- AEterna Zentaris portfolio CI